The CD133+ subset of glioma cells is known for its strong self-renewal and proliferation abilities.85, 86, 87 Compared to CD133- cells, CD133+ GSCs contribute significantly to tumor metastasis, recurrence, and resistance to chemotherapy, thereby accelerating glioma progression and leading to a poor prognosis [85–87]. This evidence concerns the gene PROM1 and neoplasm.